Trials / Completed
CompletedNCT07030127
A Study of LY3985863 in Healthy Participants
A Phase 1, Participant- and Investigator-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Doses of LY3985863 in Healthy Chinese Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate how well LY3985863 is tolerated and what side effects may occur in healthy Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3985863 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2025-08-11
- Primary completion
- 2026-02-24
- Completion
- 2026-02-24
- First posted
- 2025-06-22
- Last updated
- 2026-03-11
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07030127. Inclusion in this directory is not an endorsement.